国际皮肤性病学杂志    2006 32 (4): 260-263   ISSN: 2096-5540  CN: 32-1880/R   侵袭性曲霉病的治疗进展 崔凡, 刘维达 中国医学科学院、中国协医科大学皮肤病研究所, 南京 210042 收稿日期 2005-11-16  修回日期 null  网络版发布日期 null 参考文献  [1] Perfect JR,Cox GM,Lee JY,et al.The impact of culture isolation of Aspergillus species:a hospital-based survey of aspergillosis.Clin Infect Dis,2001,33:1824-1833. [2] Ostrosky-Zeichner L,Marr KA,Rex JH,et al.Amphotericin B:time for a new "gold standard".Clin Infect Dis,2003,37:415-425. [3] Lin SJ,Schranz J,Teutsch SM.Aspergillosis case-fatality rate:systematic review of the literature.Clin Infect Dis,2001,32:358-366. [4] Harbarth S,Pestotnik SL,Lloyd JF,et al.The epidemiology of nephrotoxicity associated with conventional amphotericin B therapy.Am J Med,2001,111:528-534. [5] Drew RH,Dodds Ashley E,Benjamin DK Jr,et al.Comparative safety of amphotericin B lipid complex and amphotericin B deoxycholate as aerosolized antifungal prophylaxis in lung-transplant recipients.Transplantation,2004,77:232-237. [6] Alexander BD,Wingard JR.Study of renal safety in amphotericin B lipid complex-treated patients.Clin Infect Dis,2005,40(Suppl 6):S414-421. [7] Chandrasekar PH,Ito JI.Amphotericin B lipid complex in the management of invasive aspergillosis in immunocompromised patients.Clin Infect Dis,2005,40(Suppl 6):S392-400. [8] Ito JI,Chandrasekar PH,Hooshmand-Rad R.Effectiveness of amphotericin B lipid complex (ABLC) treatment in allogeneic hematopoietic cell transplant (HCT) recipients with invasive aspergillosis (IA).Bone Marrow Transplant,2005,36:873-877. [9] Denning DW,Ribaud P,Milpied N,et al.Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis.Clin Infect Dis,2002,34:563-571. [10] Herbrecht R,Denning DW,Patterson TF,et al.Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.N Engl J Med,2002,347:408-415. [11] Lutsar I,Roffey S,Troke P.Voriconazole concentrations in the cerebrospinal fluid and brain tissue of guinea pigs and immunocompromised patients.Clin Infect Dis,2003,37:728-732. [12] Schwartz S,Thiel E.Update on the treatment of cerebral aspergillosis.Ann Hematol,2004,83 (Suppl 1):S42-44. [13] Stone JA,Holland SD,Wickersham PJ,et al.Single-and multiple-dose pharmacokinetics of caspofungin in healthy men.Antimicrob Agents Chemother,2002,46:739-745. [14] Walsh TJ,Teppler H,Donowitz GR,et al.Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.N Engl J Med,2004,351:1391-402. [15] Kartsonis NA,Saah AJ,Joy Lipka C,et al.Salvage therapy with caspofungin for invasive aspergillosis:results from the caspofungin compassionate use study.J Infect,2005,50:196-205. [16] Pancham S,Hemmaway C,New H,et al.Caspofungin for invasive fungal infections:combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation.Pediatr Transplant,2005,9:254-257. [17] Steinbach WJ,Stevens DA.Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis.Clin Infect Dis,2003,37(Suppl 3):S157-187. [18] Nemunaitis J,Shannon-Dorcy K,Appelbaum FR,et al.Long-term follow-up of patients with invasive fungal disease who received adjunctive therapy with recombinant human macrophage colony-stimulating factor.Blood,1993,82:1422-1427. [19] Denning DW,Marinus A,Cohen J,et al.An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients:diagnosis and therapeutic outcome.EORTC Invasive Fungal Infections Cooperative Group.J Infect,1998,37:173-180. [20] Petraitis V,Petraitiene R,Sarafandi AA,et al.Combination therapy in treatment of experimental pulmonary aspergillosis:synergistic interaction between an antifungal triazole and an echinocandin.J Infect Dis,2003,187:1834-1843. [21] Steinbach WJ,Stevens DA,Denning DW.Combination and sequential antifungal therapy for invasive aspergillosis:review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.Clin Infect Dis,2003,37(Suppl 3):S188-224. [22] Sionov E,Mendlovic S,Segal E.Experimental systemic murine aspergillosis:treatment with polyene and caspofungin combination and G-CSF.J Antimicrob Chemother,2005,56:594-597. [23] Ehrmann S,Bastides F,Gissot V,et al.Cerebral aspergillosis in the critically ill:two cases of successful medical treatment.Intensive Care Med,2005,31:738-742. [24] Dinser R,Grgic A,Kim YJ,et al.Successful treatment of disseminated aspergillosis with the combination of voriconazole,caspofungin,granulocyte transfusions,and surgery followed by allogeneic blood stem cell transplantation in a patient with primary failure of an autologous stem cell graft.Eur J Haematol,2005,74:438-441. [25] Dannaoui E,Persat F,Monier MF,et al.In-vitro susceptibility of Aspergillus spp.isolates to amphotericin B and itraconazole.J Antimicrob Chemother,1999,44:553-555. [26] Mosquera J,Denning DW.Azole cross-resistance in Aspergillus fumigatus.Antimicrob Agents Chemother,2002,46:556-557. [27] Sutton DA,Sanche SE,Revankar SG,et al.In vitro amphotericin B resistance in clinical isolates of Aspergillus terreus,with a head-to-head comparison to voriconazole.J Clin Microbiol,1999,37:2343-2345. [28] Chandrasekar PH,Cutright JL,Manavathu EK.Aspergillus:rising frequency of clinical isolation and continued susceptibility to antifungal agents,1994-1999.Diagn Microbiol Infect Dis,2001,41:211-214. [29] Kontoyiannis DP,Lewis RE,Sagar N,et al.Itraconazole-amphotericin B antagonism in Aspergillus fumigatus:an E-test-based strategy.Antimicrob Agents Chemother,2000,44:2915-2918. 通讯作者: